Pair Name | Toosendanin, Irinotecan | ||
Phytochemical Name | Toosendanin (PubChem CID: 9851101 ) | ||
Anticancer drug Name | Irinotecan (PubChem CID: 60838 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Toosendanin, Irinotecan | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Autophagy | |||
Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
Down-regulation | Expression | CTSB | hsa1508 | |
Down-regulation | Expression | CTSD | hsa1509 | |
In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
MDA-MB-436 | Invasive breast carcinoma | Homo sapiens (Human) | CVCL_0623 | |
In Vivo Model | MDA-MB-231 cells stably expressing RFP-GFP-LC3 were suspended in a 1:1 ratio in serum-free DMEM medium with a matrigel basement membrane matrix and inoculated subcutaneously (5×10⁶/site) in the right armpit. | |||
Result | The data showed that TSN blocked 7-ethyl-10-hydroxycamptothecin (SN-38)/irinotecan-induced protective autophagy, and significantly induced apoptosis in TNBC cells and tumor xenograft models when compared to SN-38/irinotecan alone group. |
No. | Title | Href |
---|---|---|
1 | Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy. Chin Med. 2022 May 6;17(1):55. doi: 10.1186/s13020-022-00605-8. | Click |